Verve Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Verve Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q2 2024.
  • Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $11.6M, a 29.2% increase year-over-year.
  • Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $40.1M, a 35.1% increase year-over-year.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $35.1M, a 56.2% increase from 2022.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.5M, a 218% increase from 2021.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.07M, a 732% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $40.1M $11.6M +$2.63M +29.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $37.4M $10.3M +$2.32M +28.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $35.1M $9.25M +$2.55M +38% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $32.6M $8.83M +$2.91M +49.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $29.7M $9.01M +$3.36M +59.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $26.3M $8.02M +$3.82M +90.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $22.5M $6.71M +$3.95M +143% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $18.5M $5.92M +$3.63M +158% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $14.9M $5.65M +$4.3M +318% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $10.6M $4.2M +$3.53M +527% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $7.07M $2.76M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $2.29M +$2.08M +977% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $1.35M +$1.25M +1251% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $670K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 $213K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $100K Apr 1, 2020 Jun 30, 2020 10-Q/A 2021-08-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.